Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

Pooling 11 trials in more than 85,000 patients, GLP-1 receptor agonists reduced clinically important kidney failure events as well as heart attacks, strokes, and death in people with type 2 diabetes.